Related Experiment Video
Updated: Jul 4, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Novel advances in pancreatic cancer treatment
Michel Vulfovich1, Caio Rocha-Lima
1Sylvester Comprehensive Cancer Center/University of Miami School of Medicine, Miami, FL, USA. mvulfovich@med.miami.edu
Abstract:
Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement in survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase inhibitors) to gemcitabine compared with gemcitabine alone have been disappointing. A small gain in median survival by adding erlotinib to gemcitabine has recently been reported. We herein review novel agents in pancreatic cancer that may change the current nihilistic approach in the management of this challenging disease.
Insights
Advanced pancreatic cancer treatment has seen little progress. Novel agents are reviewed to improve outcomes beyond gemcitabine chemotherapy and targeted therapies, offering hope for this challenging disease.
Area of Science:
- Oncology
- Medical Research
Background:
- Advanced pancreatic cancer treatment remains challenging with limited progress.
- Gemcitabine has been the standard chemotherapy for over a decade, offering minimal benefit in advanced and metastatic disease.
- Combinations of gemcitabine with other chemotherapy agents or molecular targeting agents have largely failed to improve survival meaningfully.
Purpose of the Study:
- To review novel therapeutic agents for pancreatic cancer.
- To explore potential new strategies beyond current standards of care.
- To address the limited progress and "nihilistic approach" in managing advanced pancreatic cancer.
Main Methods:
- Review of randomized trials and published literature.
- Analysis of outcomes for gemcitabine-based regimens.
- Evaluation of novel agents and their potential impact.
Main Results:
- Single-agent gemcitabine provides limited benefit in advanced pancreatic cancer.
- Addition of various agents (e.g., cetuximab, bevacizumab) to gemcitabine has yielded disappointing results.
- A modest survival gain was recently reported with erlotinib plus gemcitabine.
Conclusions:
- Current treatment options for advanced pancreatic cancer are inadequate.
- Novel agents are crucial to overcome the limitations of existing therapies.
- Further research into new treatments may offer improved outcomes for patients with pancreatic cancer.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...